Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) – 2019 to 2024

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: May 28, 2019
Clear
SKU: GMS2023 Category:

The global market for liquid biopsy is projected to grow to USD 2,212 million by 2024, growing at a CAGR of 22.62% over the forecast period. Some of the key factors driving this market’s growth include rising cancer incidence, growing preference for non-invasive procedures, and funding availability for R&D on liquid biopsy.

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 1

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 2

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 3

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 4

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 5

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 6

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 7

Liquid Biopsy Market by Cancer Type (Breast, Lung, Prostate, Colorectal), Product (Assay Kits, Instruments), Circulating Biomarkers (Circulating Tumor DNA, Circulating Tumor Cells, Cell-Free DNA), End User (Reference Laboratory) - 2019 to 2024 8

1 Global Liquid Biopsy Market 
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Liquid Biopsy Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Liquid Biopsy Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Liquid Biopsy Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Liquid Biopsy Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Liquid Biopsy Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Liquid Biopsy Market – By Product (Market Size – & million/billion)
8.1 Assays Kits
8.2 Instruments
8.3 Services

9 Global Liquid Biopsy Market – By Circulating Biomarker
9.1 Circulating Tumor Cells (CTCs)
9.2 Circulating Tumor DNA (ctDNA)
9.3 Cell-Free DNA (cfDNA)
9.4 Extracellular Vesicles (EVs)
9.5 Other

10 Global Liquid Biopsy Market – By Application
10.1 Oncology
10.2 Non-Cancer Application

11 Global Liquid Biopsy Market – By End-User
11.1 Reference Laboratories
11.2 Hospitals and Physician Laboratories
11.3 Academic and Research Centers
11.4 Other End Users

12 Global Liquid Biopsy Market – By Geography (Market Size – & million/billion)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 U.K
12.3.2 Germany
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Rest of the World
12.5.1 South America
12.5.2 Middle East
12.5.3 Africa

13 Global Liquid Biopsy Market – Entropy
13.1 New product launches
13.2 M&A’s, collaborations, JVs and partnerships

14 Global Liquid Biopsy Market Company Profile (Key Players)
14.1 Market Share, Company Revenue, Products, M&A, Developments
14.2 Qiagen N.V.
14.3 Biocept, Inc
14.4 Bio-Rad Laboratories, Inc.
14.5 Roche Diagnostics
14.6 Myriad Genetics, Inc
14.7 Menarini-Silicon Biosystems
14.8 Guardant Health, Inc.
14.9 Trovagene, Inc.
14.10 Genomic Health, Inc.
14.11 Raindance Technologies, Inc
14.12 Company 11 & more

15 Global Liquid Biopsy Market – Appendix
15.1 Sources
15.2 Abbreviations